Study protocol for NeuroCARE: a randomised controlled trial of a psychological intervention for caregivers of patients with primary malignant brain tumours

• Published in: BMJ open Vol. 13; no. 9; p. e069410
• Main Authors: Forst, Deborah Anne, Rhee, John Y, Mesa, Michelle Marie, Podgurski, Alyx F, Strander, Sumita Madhok, Datta, Shibani, Kaslow-Zieve, Emilia, Horick, Nora K, Greer, Joseph A, El-Jawahri, Areej, Sannes, Timothy S, Temel, Jennifer S, Jacobs, Jamie
• Format: Journal Article
• Language: English
• Published: London BMJ Publishing Group LTD 07.09.2023; BMJ Publishing Group
• Series: Protocol
• Subjects: Anxiety disorders; Brain cancer; Caregivers; Consent; Electronic health records; Intervention; Mindfulness; Nervous system; Oncology; Outpatient care facilities; Patients; Pilot projects; Post traumatic stress disorder; Report writing; Telemedicine; Tumors; United States > US; Massachusetts
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2022-069410

Introduction Caregivers of patients with primary malignant brain tumours experience substantial psychological distress while caring for someone with a progressive, life-limiting neurological illness. However, there are few interventions aimed at addressing the psychosocial needs of this population. We developed and are testing a population-specific, evidence-based, telehealth intervention (NeuroCARE) to reduce anxiety symptoms and improve psychosocial functioning in this caregiver population. Methods and analysis This study is a non-blinded, randomised controlled trial of a psychological intervention for caregivers of patients with primary malignant brain tumours receiving care at the Massachusetts General Hospital Cancer Center or Dana-Farber Cancer Institute. We will enrol 120 caregivers who screen positive for heightened anxiety. Participants will be randomised 1:1 to the NeuroCARE intervention or a usual care control condition. Caregivers assigned to NeuroCARE will complete six individual telehealth sessions with a trained behavioural health specialist over 12 weeks. Caregivers randomised to the control condition will receive usual care, including possible referral to social work or other appropriate resources. Participants will complete self-report questionnaires at baseline and 11 weeks and 16 weeks postrandomisation. The primary outcome is anxiety symptoms at 11 weeks among NeuroCARE participants, compared with usual care. Secondary outcomes include caregiver-reported depressive symptoms, quality of life, caregiver burden, caregiving self-efficacy, perceived coping skills and post-traumatic stress disorder symptoms. We also will explore potential mediators of the NeuroCARE effect on caregiver anxiety symptoms. Ethics and dissemination The study is funded by a Career Development Award from Conquer Cancer, the American Society of Clinical Oncology Foundation (award number 2019CDA-7743456038) and approved by the Dana-Farber/Harvard Cancer Center Institutional Review Board (Protocol #19-250 V.10.1). The study will be reported in accordance with the Consolidated Standards of Reporting Trials statement for non-pharmacological trials. Results will be presented at scientific meetings and in peer-reviewed journals. Trial registration number NCT04109209